Grey Matters Health Inc., a Canadian-based healthcare company, is moving forward with plans to open its first PET neuroimaging clinic in the United States, located in Davie, Florida. The facility is expected to complete its first brain scan by the end of September 2026. This development aligns with the company’s broader strategy to establish a national presence and provide expanded access to specialized diagnostic imaging for conditions affecting the brain. The clinic will serve as the flagship for the company’s NovaScan Neuroimaging ClinicsTM network.
Christopher J. Moreau, the CEO of Grey Matters, shared his enthusiasm for the clinic’s progress and the team’s efforts to ensure a smooth launch. The upcoming facility will integrate newly FDA-approved brain imaging technology, allowing Grey Matters to offer high-quality, patient-focused diagnostic services. The clinic’s design emphasizes both comfort and efficiency, ensuring an improved experience for individuals undergoing brain scans.
Clinic Location and Facility
The inaugural clinic will be situated in the HCA Florida University Medical Office Building in Davie, Florida, which is part of the HCA Florida University Hospital campus. This location will be the first U.S. site to provide dedicated brain PET scans. The scans will aid in the early identification of beta-amyloid plaques linked to Alzheimer’s disease and help diagnose other neurodegenerative conditions such as frontotemporal dementia, Parkinson’s, Lewy Body Dementia, and specific neuro-oncological disorders. The facility aims to streamline access to these critical diagnostic tools.
The clinic will utilize the CareMiBrain™ system, a newly U.S. FDA-approved seated diagnostic brain PET scanner. Unlike traditional PET/CT scanners, the CareMiBrain™ system does not require a CT component to produce clear, high-resolution images of the brain. This advancement results in a 25% reduction in radiation exposure for patients, making the scanning process both safer and more comfortable, while still maintaining diagnostic precision.
Insurance Coverage and Referrals
For patients aged 65 and over, brain PET scans are covered by Medicare, Medicaid, and private insurance, making the clinic a viable option for those in need of these diagnostic services. Referrals to the NovaScan Neuroimaging ClinicsTM will come from neurologists, geriatricians, and primary care physicians, who will recommend the facility for comprehensive brain health evaluations. This structured referral process ensures that patients receive care from trusted medical professionals.
Addressing a Growing Market for Alzheimer’s Detection
The opening of the clinic coincides with a surge in demand for Alzheimer’s disease diagnostics. Two FDA-approved monoclonal antibody therapies, Leqembi and Kisunla, have recently become available to patients. Leqembi, developed by Eisai and Biogen, and Kisunla, developed by Eli Lilly, are both designed to slow the progression of the disease and are covered by Medicare, Medicaid, and private insurance. These treatments are only eligible for patients who have confirmed beta-amyloid plaque buildup in the brain, which must be detected via brain scans or spinal taps.
The introduction of these innovative therapies has significantly fueled the market for brain-specific PET scans, generating a billion-dollar opportunity in the diagnostics and treatment space. However, the current supply of PET scanners across the U.S. is insufficient to meet the growing demand. Most existing scanners are PET/CT hybrid systems, which are primarily used for oncology and cardiac imaging. This limitation creates scheduling challenges for patients who need brain-specific scans. Grey Matters aims to address this shortage by expanding its network of NovaScan Neuroimaging Clinics, which will offer greater access to these essential diagnostic services.
Future Expansion and Vision
Looking ahead, the company envisions a nationwide rollout of these clinics, enabling more patients to benefit from early detection and advanced diagnostics. By focusing on the brain-specific needs of the medical community and patient population, Grey Matters Health Inc. is positioning itself as a key player in addressing the rising prevalence of neurodegenerative conditions.
Grey Matters Health Inc. has established itself as a leader in providing brain-dedicated PET scanning services. The company is committed to advancing its role in the early detection of Alzheimer’s disease and other neurological disorders, while also offering specialized support for neuro-oncology applications. With its new U.S. clinic set to open this September, Grey Matters is taking a pivotal step in its mission to improve access to cutting-edge diagnostic imaging solutions for patients and healthcare providers nationwide.
